Year: 2014

Functional Genomics Approaches to Identify Ovarian Cancer Genes

Cancer arises from progressive acquisition of alterations in DNA of cells…

Read on

Determining the Molecular Drivers of Low-Grade Serous Ovarian Cancer

Low-grade serous ovarian cancer is a rare type of ovarian cancer that is profoundly resistant to standard chemotherapy options. Response rates to chemotherapy are typically less than 5%…

Read on

A Cellular Switch to Modulate BRCA2-mediated Tumor Progression

BRCA2 (Breast Cancer Susceptibility Gene 2) was originally identified as one of two genes responsible for familial inherited breast and ovarian cancer…

Read on

New Type of Experimental Drug for Ovarian Cancer

Ovarian cancer is the most lethal of the gynecological cancers, and treatment is often complicated by diagnosis at late stages and the eventual development of resistance to conventional chemotherapy upon recurrence…

Read on

Rational Design of Effective Multi-modal Ovarian Cancer Immunotherapy

Ovarian cancer elicits strong anti-cancer immunity, but the cancer is not eliminated…

Read on

Molecular Biomarkers to Predict PARP Inhibitor Response in Ovarian Cancer

PARP inhibitors are a promising new class of drugs for the treatment of ovarian cancer. They work by taking advantage of a cancer’s inability to repair its own DNA…

Read on

In vivo Programming of Ovarian Tumor-reactive T-cells Using Nanoparticles

Ovarian cancer is often diagnosed after tumor cells have already spread (metastasized) from the ovary, so it is difficult to remove them entirely using surgery and chemotherapy…

Read on

Chromatin Regulatory Mechanisms in Ovarian Cancer

The goal of this project is to understand how proteins that control the packaging and transmission of our genetic information, called transcription factors, are deregulated in ovarian cancer and to leverage this understanding to develop new…

Read on

Ovarian Cancer Surrogates to Study Platinum Resistance

Although most patients with ovarian cancer respond well to optimal surgical debulking and platinum-based chemotherapy, the majority of them will relapse and in this setting, cure is uncommon…

Read on

Rational Combinations of Novel Biologic Agents for Ovarian Cancer Therapy

Improvement in the treatment ovarian cancer has reached a plateau using our current treatment arsenal…

Read on

Computationally-guided Characterization of Therapy-resistant Ovarian Tumors

Although the majority of patients who present with an aggressive ovarian tumor respond well to initial treatment, 70-90% of them will relapse and die of their disease…

Read on

A Bioinformatic Screen Identifies POLQ Overexpression in Ovarian Cancers

In the United States, there are approximately 23,000 new cases of ovarian cancer diagnosed per year, and over 15,000 women die from the disease…

Read on